-
公开(公告)号:US20070048317A1
公开(公告)日:2007-03-01
申请号:US11539271
申请日:2006-10-06
申请人: CHARLES HART , Stavros Topouzis , Debra Gilbertson
发明人: CHARLES HART , Stavros Topouzis , Debra Gilbertson
IPC分类号: A61K39/395
CPC分类号: A61K39/3955 , A61K38/1808 , A61K38/1825 , A61K38/1841 , A61K38/1866 , A61K38/1875 , C04B38/06 , C04B2111/00224 , C04B2111/00612 , C07K14/52 , C07K16/22 , C07K16/2863 , C07K2317/34 , C07K2319/00 , C12N2799/022 , C04B20/008 , C04B35/2641 , C04B35/50 , C04B35/64 , C04B38/0054 , C04B38/007 , C04B41/4578 , A61K2300/00
摘要: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
摘要翻译: 公开了用于减少哺乳动物细胞增殖或细胞外基质产生的材料和方法。 所述方法包括向哺乳动物施用包含治疗有效量的zvegf4拮抗剂与药学上可接受的递送载体的组合物。 示例性的zvegf4拮抗剂包括抗zvegf4抗体,抑制性多核苷酸,zvegf4激活的抑制剂和zvegf4的有丝分裂失活的受体结合变体。 所述材料和方法尤其用于治疗肾脏,肝脏和骨骼的纤维增生性疾病。
-
公开(公告)号:US2143773A
公开(公告)日:1939-01-10
申请号:US7173836
申请日:1936-03-30
申请人: CHARLES HART
发明人: CHARLES HART
IPC分类号: C01B32/50
CPC分类号: C01B32/50
-
公开(公告)号:US20070048316A1
公开(公告)日:2007-03-01
申请号:US11538706
申请日:2006-10-04
申请人: CHARLES HART , STAVROS TOPOUZIS , DEBRA GILBERTSON
发明人: CHARLES HART , STAVROS TOPOUZIS , DEBRA GILBERTSON
IPC分类号: A61K39/395
CPC分类号: A61K39/3955 , A61K38/1808 , A61K38/1825 , A61K38/1841 , A61K38/1866 , A61K38/1875 , C04B38/06 , C04B2111/00224 , C04B2111/00612 , C07K14/52 , C07K16/22 , C07K16/2863 , C07K2317/34 , C07K2319/00 , C12N2799/022 , C04B20/008 , C04B35/2641 , C04B35/50 , C04B35/64 , C04B38/0054 , C04B38/007 , C04B41/4578 , A61K2300/00
摘要: Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone.
摘要翻译: 公开了用于减少哺乳动物细胞增殖或细胞外基质产生的材料和方法。 所述方法包括向哺乳动物施用包含治疗有效量的zvegf4拮抗剂与药学上可接受的递送载体的组合物。 示例性的zvegf4拮抗剂包括抗zvegf4抗体,抑制性多核苷酸,zvegf4激活的抑制剂和zvegf4的有丝分裂失活的受体结合变体。 所述材料和方法尤其用于治疗肾脏,肝脏和骨骼的纤维增生性疾病。
-
-